23:07 , Oct 11, 2018 |  BC Week In Review  |  Financial News

Cancer company Rgenix raises $40M series C

Rgenix Inc. (New York, N.Y.) raised $40 million on Oct. 9 in a series C round led by Lepu Medical. New investors Oceanpine Capital and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259)...
14:44 , Jan 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest stimulating cholesterol efflux in phagocytes by promoting LXR expression could help treat MS. In a mouse model of lysolecithin-induced MS, cholesterol accumulation in the membranes of lesion-infiltrating phagocytes...
23:32 , Jan 4, 2018 |  BC Extra  |  Preclinical News

Cholesterol efflux in phagocytes may promote remyelination

A report published in Science suggests stimulating cholesterol efflux in phagocytes may promote remyelination in aged individuals, offering a potential regenerative strategy for patients who have had multiple sclerosis or other demyelinating disorders for long...
23:44 , Nov 3, 2017 |  BioCentury  |  Product Development

Liver X factor

Rgenix Inc. is preparing to test its RGX-104 in combination with checkpoint inhibitors after Phase I data confirmed the company’s belief that the liver X receptor agonist depletes suppressive immune cells and increases T cell...
18:57 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Rgenix reports Phase I data for cancer compound RGX-104

Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. RGX-104...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
13:21 , May 31, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Mouse intestinal organoids could be used to model intestinal drug metabolism and toxicity. The organoids were generated by treating primary mouse crypt cells isolated from the small intestine with a cocktail of...
00:46 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

RGX-104: Ph I started

Rgenix began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral RGX-104 in about 80 patients. Rgenix has exclusive, worldwide rights to RGX-104 from GlaxoSmithKline. Rgenix Inc. , New York, N.Y.  GlaxoSmithKline plc...
17:32 , Jan 11, 2017 |  BC Extra  |  Clinical News

Allergan discloses Phase II miss in LXR program

Allergan plc (NYSE:AGN) said VTP-38543 did not show proof of concept in a Phase II trial to treat atopic dermatitis. Allergan acquired the liver X receptor beta ( NR1H2 ; LXR-b) agonist via its $639...
17:43 , Nov 15, 2016 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles An HDL-mimicking nanoparticle could safely deliver atherosclerosis therapies to the liver. In vitro assays and in vivo testing of a library of HDL- mimicking nanoparticles identified one nanoparticle that induced cholesterol efflux from...